51
|
Ramirez-Medina E, O’Donnell V, Silva E, Espinoza N, Velazquez-Salinas L, Moran K, Daite DA, Barrette R, Faburay B, Holland R, Gladue DP, Borca MV. Experimental Infection of Domestic Pigs with an African Swine Fever Virus Field Strain Isolated in 2021 from the Dominican Republic. Viruses 2022; 14:v14051090. [PMID: 35632831 PMCID: PMC9145207 DOI: 10.3390/v14051090] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 05/10/2022] [Accepted: 05/12/2022] [Indexed: 12/16/2022] Open
Abstract
African swine fever virus (ASFV) is the etiological agent of African swine fever (ASF), a disease of domestic and wild swine that has spread throughout a large geographical area including Central Europe, East and Southeast Asia, and Southern Africa. Typically, the clinical presentation of the disease in affected swine heavily depends on the virulence of the ASFV strain. Very recently, ASFV was detected in the Dominican Republic (DR) and Haiti, constituting the first diagnosis of ASFV in more than 40 years in the Western hemisphere. In this report, the clinical presentation of the disease in domestic pigs inoculated with an ASFV field strain isolated from samples collected in the DR (ASFV-DR21) was observed. Two groups of domestic pigs were inoculated either intramuscularly (IM) or oronasally (ON) with ASFV-DR21 (104 hemadsorbing dose-50% (HAD50)). A group of naïve pigs (designated as the contact group) was co-housed with the ASFV-DR21 IM-inoculated animals to evaluate ASFV transmission and disease manifestation. Animals inoculated IM with ASFV-DR21 developed an acute disease leading to humane euthanasia at approximately day 7 post-inoculation (pi). Interestingly, animals inoculated via the ON route with ASFV-DR21 developed a heterogeneous pattern of disease kinetics. One animal developed an acute form of the disease and was euthanized on day 7 pi, another animal experienced a protracted presentation of the disease with euthanasia by day 16 pi, and the remaining two animals presented a milder form of the disease, surviving through the 28-day observational period. The contact animals also presented with a heterogenous presentation of the disease. Three of the animals presented protracted but severe forms of the disease being euthanized at days 14, 15 and 21 pi. The other two animals presented with a milder form of the disease, surviving the entire observational period. In general, virus titers in the blood of animals in all study groups closely followed the clinical presentation of the disease, both in length and extent. Importantly, all animals presenting with a prolonged form of the disease, as well as those surviving throughout the observational period, developed a strong ASFV-specific antibody response. These results suggest that ASFV-DR21, unless inoculated parenterally, produces a spectrum of clinical disease, with some animals experiencing an acute fatal form while others presented with a mild transient disease accompanied by the induction of a strong antibody response. At the time of publication, this is the first report characterizing the virulent phenotype of an ASFV field strain isolated from samples collected in the DR during the 2021 outbreak and provides information that may be used in developing epidemiological management measures to control ASF on the island of Hispaniola.
Collapse
Affiliation(s)
- Elizabeth Ramirez-Medina
- Plum Island Animal Disease Center, Agricultural Research Service, USDA, Greenport, NY 11944, USA; (E.R.-M.); (E.S.); (N.E.); (L.V.-S.)
| | - Vivian O’Donnell
- Plum Island Animal Disease Center, Animal and Plant Health Inspection Service, USDA, Greenport, NY 11944, USA; (V.O.); (K.M.); (D.A.D.); (R.B.); (B.F.); (R.H.)
| | - Ediane Silva
- Plum Island Animal Disease Center, Agricultural Research Service, USDA, Greenport, NY 11944, USA; (E.R.-M.); (E.S.); (N.E.); (L.V.-S.)
| | - Nallely Espinoza
- Plum Island Animal Disease Center, Agricultural Research Service, USDA, Greenport, NY 11944, USA; (E.R.-M.); (E.S.); (N.E.); (L.V.-S.)
| | - Lauro Velazquez-Salinas
- Plum Island Animal Disease Center, Agricultural Research Service, USDA, Greenport, NY 11944, USA; (E.R.-M.); (E.S.); (N.E.); (L.V.-S.)
| | - Karen Moran
- Plum Island Animal Disease Center, Animal and Plant Health Inspection Service, USDA, Greenport, NY 11944, USA; (V.O.); (K.M.); (D.A.D.); (R.B.); (B.F.); (R.H.)
| | - Dee Ann Daite
- Plum Island Animal Disease Center, Animal and Plant Health Inspection Service, USDA, Greenport, NY 11944, USA; (V.O.); (K.M.); (D.A.D.); (R.B.); (B.F.); (R.H.)
| | - Roger Barrette
- Plum Island Animal Disease Center, Animal and Plant Health Inspection Service, USDA, Greenport, NY 11944, USA; (V.O.); (K.M.); (D.A.D.); (R.B.); (B.F.); (R.H.)
| | - Bonto Faburay
- Plum Island Animal Disease Center, Animal and Plant Health Inspection Service, USDA, Greenport, NY 11944, USA; (V.O.); (K.M.); (D.A.D.); (R.B.); (B.F.); (R.H.)
| | - Robin Holland
- Plum Island Animal Disease Center, Animal and Plant Health Inspection Service, USDA, Greenport, NY 11944, USA; (V.O.); (K.M.); (D.A.D.); (R.B.); (B.F.); (R.H.)
| | - Douglas P. Gladue
- Plum Island Animal Disease Center, Agricultural Research Service, USDA, Greenport, NY 11944, USA; (E.R.-M.); (E.S.); (N.E.); (L.V.-S.)
- Correspondence: (D.P.G.); (M.V.B.)
| | - Manuel V. Borca
- Plum Island Animal Disease Center, Agricultural Research Service, USDA, Greenport, NY 11944, USA; (E.R.-M.); (E.S.); (N.E.); (L.V.-S.)
- Correspondence: (D.P.G.); (M.V.B.)
| |
Collapse
|
52
|
Tran XH, Phuong LTT, Huy NQ, Thuy DT, Nguyen VD, Quang PH, Ngôn QV, Rai A, Gay CG, Gladue DP, Borca MV. Evaluation of the Safety Profile of the ASFV Vaccine Candidate ASFV-G-ΔI177L. Viruses 2022; 14:v14050896. [PMID: 35632638 PMCID: PMC9147362 DOI: 10.3390/v14050896] [Citation(s) in RCA: 38] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 04/20/2022] [Accepted: 04/20/2022] [Indexed: 01/09/2023] Open
Abstract
African swine fever (ASF) is the cause of a recent pandemic that is posing a threat to much of the world swine production. The etiological agent, ASF virus (ASFV), infects domestic and wild swine, producing a variety of clinical presentations depending on the virus strain and the genetic background of the pigs infected. No commercial vaccine is currently available, although recombinant live attenuated vaccine candidates have been shown to be efficacious. In addition to determining efficacy, it is paramount to evaluate the safety profile of a live attenuated vaccine. The presence of residual virulence and the possibility of reversion to virulence are two of the concerns that must be evaluated in the development of live attenuated vaccines. Here we evaluate the safety profile of an efficacious live attenuated vaccine candidate, ASFV-G-ΔI177L. Results from safety studies showed that ASFV-G-ΔI177L remains genetically stable and phenotypically attenuated during a five-passage reversion to virulence study in domestic swine. In addition, large-scale experiments to detect virus shedding and transmission confirmed that even under varying conditions, ASFV-G-ΔI177L is a safe live attenuated vaccine.
Collapse
Affiliation(s)
- Xuan Hanh Tran
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City 70000, Vietnam; (L.T.T.P.); (N.Q.H.); (D.T.T.); (N.V.D.); (P.H.Q.); (Q.V.N.)
- Correspondence: (X.H.T.); (D.P.G.); (M.V.B.)
| | - Le Thi Thu Phuong
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City 70000, Vietnam; (L.T.T.P.); (N.Q.H.); (D.T.T.); (N.V.D.); (P.H.Q.); (Q.V.N.)
| | - Nguyen Quang Huy
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City 70000, Vietnam; (L.T.T.P.); (N.Q.H.); (D.T.T.); (N.V.D.); (P.H.Q.); (Q.V.N.)
| | - Do Thanh Thuy
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City 70000, Vietnam; (L.T.T.P.); (N.Q.H.); (D.T.T.); (N.V.D.); (P.H.Q.); (Q.V.N.)
| | - Van Dung Nguyen
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City 70000, Vietnam; (L.T.T.P.); (N.Q.H.); (D.T.T.); (N.V.D.); (P.H.Q.); (Q.V.N.)
| | - Pham Hào Quang
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City 70000, Vietnam; (L.T.T.P.); (N.Q.H.); (D.T.T.); (N.V.D.); (P.H.Q.); (Q.V.N.)
| | - Quách Võ Ngôn
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City 70000, Vietnam; (L.T.T.P.); (N.Q.H.); (D.T.T.); (N.V.D.); (P.H.Q.); (Q.V.N.)
| | - Ayushi Rai
- Plum Island Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY 11944, USA;
| | - Cyril G. Gay
- Agricultural Research Service, U.S. Department of Agriculture, Beltsville, MD 20705, USA;
| | - Douglas Paul Gladue
- Plum Island Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY 11944, USA;
- Correspondence: (X.H.T.); (D.P.G.); (M.V.B.)
| | - Manuel Victor Borca
- Plum Island Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY 11944, USA;
- Correspondence: (X.H.T.); (D.P.G.); (M.V.B.)
| |
Collapse
|
53
|
Gladue DP, Borca MV. Recombinant ASF Live Attenuated Virus Strains as Experimental Vaccine Candidates. Viruses 2022; 14:v14050878. [PMID: 35632620 PMCID: PMC9146452 DOI: 10.3390/v14050878] [Citation(s) in RCA: 39] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 04/17/2022] [Accepted: 04/21/2022] [Indexed: 11/16/2022] Open
Abstract
African swine fever (ASF) is causing a pandemic affecting swine in a large geographical area of the Eastern Hemisphere, from Central Europe to East and Southeast Asia, and recently in the Americas, the Dominican Republic and Haiti. The etiological agent, ASF virus (ASFV), infects both domestic and wild swine and produces a variety of clinical presentations depending on the virus strain and the genetics of the pigs infected. No commercial vaccines are currently available, although experimental recombinant live attenuated vaccine candidates have been shown to be efficacious in protecting animals against disease when challenged with homologous virulent strains. This review attempts to systematically provide an overview of all the live attenuated strains that have been shown to be experimental vaccine candidates. Moreover, it aims to analyze the development of these vaccine candidates, obtained by deleting specific genes or group of genes, and their efficacy in preventing virus infection and clinical disease after being challenged with virulent isolates. This report summarizes all the experimental vaccine strains that have shown promise against the contemporary pandemic strain of African swine fever.
Collapse
|
54
|
ASF -survivors’ sera do not inhibit African swine fever virus replication in vitro. J Vet Res 2022; 66:21-27. [PMID: 35582480 PMCID: PMC8959686 DOI: 10.2478/jvetres-2022-0016] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 03/08/2022] [Indexed: 11/20/2022] Open
Abstract
Introduction African swine fever virus (ASFV) causes one of the most dangerous diseases of pigs and wild boar – African swine fever (ASF). Since its second introduction into Europe (in 2007), the disease has been spreading consistently, and now ASF-free European countries are at risk. Complex interactions between the host’s immune system and the virus have long prevented the development of a safe vaccine against ASF. This study analysed the possibility of neutralisation of the ASFV in vitro by sera collected from ASF-survivor animals. Material and Methods Two pig and three wild boar serum samples were collected from previously selected potential ASF survivors. All sera presented high antibody titres (>5 log10/mL). Primary alveolar macrophages were cultured in growth medium containing 10% and 20% concentrations of selected sera and infected with a haemadsorbing ASFV strain (Pol18_28298_O111, genotype II). The progress of infection was investigated under a light microscope by observing the cytopathic effect (CPE) and the haemadsorption phenomenon. Growth kinetics were investigated using a real-time PCR assay. Results Haemadsorption inhibition was detected in the presence of almost all selected sera; however, the inhibition of virus replication in vitro was excluded. In all samples, a CPE and decreasing quantification cycle values of the viral DNA were found. Conclusion Anti-ASFV antibodies alone are not able to inhibit virus replication. Interactions between the humoral and cellular immune response which effectively combat the disease are implicated in an ASF-survivor’s organism.
Collapse
|
55
|
Wang Z, Ai Q, Huang S, Ou Y, Gao Y, Tong T, Fan H. Immune Escape Mechanism and Vaccine Research Progress of African Swine Fever Virus. Vaccines (Basel) 2022; 10:vaccines10030344. [PMID: 35334976 PMCID: PMC8949402 DOI: 10.3390/vaccines10030344] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 02/16/2022] [Accepted: 02/17/2022] [Indexed: 02/04/2023] Open
Abstract
African swine fever virus (ASFV) is the causative agent of the epidemic of African swine fever (ASF), with virulent strains having a mortality rate of up to 100% and presenting devastating impacts on animal farming. Since ASF was first reported in China in 2018, ASFV still exists and poses a potential threat to the current pig industry. Low-virulence and genotype I strains of ASFV have been reported in China, and the prevention and control of ASF is more complicated. Insufficient understanding of the interaction of ASFV with the host immune system hinders vaccine development. Physical barriers, nonspecific immune response and acquired immunity are the three barriers of the host against infection. To escape the innate immune response, ASFV invades monocytes/macrophages and dendritic cells, thereby inhibiting IFN expression, regulating cytokine expression and the body’s inflammatory response process. Meanwhile, in order to evade the adaptive immune response, ASFV inhibits antigen presentation, induces the production of non-neutralizing antibodies, and inhibits apoptosis. Recently, significant advances have been achieved in vaccine development around the world. Live attenuated vaccines (LAVs) based on artificially deleting specific virulence genes can achieve 100% homologous protection and partial heterologous protection. The key of subunit vaccines is identifying the combination of antigens that can effectively provide protection and selecting carriers that can effectively deliver the antigens. In this review, we introduce the epidemic trend of ASF and the impact on the pig industry, analyze the interaction mechanism between ASFV and the body’s immune system, and compare the current status of potential vaccines in order to provide a reference for the development of effective ASF vaccines.
Collapse
Affiliation(s)
- Zhaoyang Wang
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China; (Z.W.); (Q.A.); (S.H.); (Y.O.); (Y.G.)
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, Guangzhou 510642, China
- Key Laboratory of Animal Vaccine Development, Ministry of Agriculture, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Qiangyun Ai
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China; (Z.W.); (Q.A.); (S.H.); (Y.O.); (Y.G.)
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, Guangzhou 510642, China
- Key Laboratory of Animal Vaccine Development, Ministry of Agriculture, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Shenglin Huang
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China; (Z.W.); (Q.A.); (S.H.); (Y.O.); (Y.G.)
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, Guangzhou 510642, China
- Key Laboratory of Animal Vaccine Development, Ministry of Agriculture, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Yating Ou
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China; (Z.W.); (Q.A.); (S.H.); (Y.O.); (Y.G.)
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, Guangzhou 510642, China
- Key Laboratory of Animal Vaccine Development, Ministry of Agriculture, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Yinze Gao
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China; (Z.W.); (Q.A.); (S.H.); (Y.O.); (Y.G.)
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, Guangzhou 510642, China
- Key Laboratory of Animal Vaccine Development, Ministry of Agriculture, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Tiezhu Tong
- Guangzhou Customs Technology Center, Guangzhou 510623, China
- Correspondence: (T.T.); (H.F.); Fax: +86-020-38295730 (T.T.); +86-20-8528-3309 (H.F.)
| | - Huiying Fan
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China; (Z.W.); (Q.A.); (S.H.); (Y.O.); (Y.G.)
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, Guangzhou 510642, China
- Key Laboratory of Animal Vaccine Development, Ministry of Agriculture, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
- Correspondence: (T.T.); (H.F.); Fax: +86-020-38295730 (T.T.); +86-20-8528-3309 (H.F.)
| |
Collapse
|
56
|
Le T, Sun C, Chang J, Zhang G, Yin X. mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases. Viruses 2022; 14:401. [PMID: 35215994 PMCID: PMC8877136 DOI: 10.3390/v14020401] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2022] [Revised: 02/12/2022] [Accepted: 02/14/2022] [Indexed: 02/04/2023] Open
Abstract
In the prevention and treatment of infectious diseases, mRNA vaccines hold great promise because of their low risk of insertional mutagenesis, high potency, accelerated development cycles, and potential for low-cost manufacture. In past years, several mRNA vaccines have entered clinical trials and have shown promise for offering solutions to combat emerging and re-emerging infectious diseases such as rabies, Zika, and influenza. Recently, the successful application of mRNA vaccines against COVID-19 has further validated the platform and opened the floodgates to mRNA vaccine's potential in infectious disease prevention, especially in the veterinary field. In this review, we describe our current understanding of the mRNA vaccines and the technologies used for mRNA vaccine development. We also provide an overview of mRNA vaccines developed for animal infectious diseases and discuss directions and challenges for the future applications of this promising vaccine platform in the veterinary field.
Collapse
Affiliation(s)
- Ting Le
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, China; (T.L.); (C.S.)
| | - Chao Sun
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, China; (T.L.); (C.S.)
| | - Jitao Chang
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, China; (T.L.); (C.S.)
| | - Guijie Zhang
- Departments of Animal Science, School of Agriculture, Ningxia University, Yinchuan 750021, China
| | - Xin Yin
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, China; (T.L.); (C.S.)
| |
Collapse
|
57
|
Zhang G, Liu W, Gao Z, Chang Y, Yang S, Peng Q, Ge S, Kang B, Shao J, Chang H. Antigenic and immunogenic properties of recombinant proteins consisting of two immunodominant African swine fever virus proteins fused with bacterial lipoprotein OprI. Virol J 2022; 19:16. [PMID: 35062983 PMCID: PMC8781047 DOI: 10.1186/s12985-022-01747-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Accepted: 01/12/2022] [Indexed: 12/16/2022] Open
Abstract
Abstract
Background
African swine fever (ASF) is a highly fatal swine disease, which threatens the global pig industry. There is no commercially available vaccine against ASF and effective subunit vaccines would represent a real breakthrough.
Methods
In this study, we expressed and purified two recombinant fusion proteins, OPM (OprI-p30-modified p54) and OPMT (OprI-p30-modified p54-T cell epitope), which combine the bacterial lipoprotein OprI with ASF virus proteins p30 and p54. Purified recombinant p30 and modified p54 expressed alone or fused served as controls. The activation of dendritic cells (DCs) by these proteins was first assessed. Then, humoral and cellular immunity induced by the proteins were evaluated in mice.
Results
Both OPM and OPMT activated DCs with elevated expression of relevant surface molecules and proinflammatory cytokines. Furthermore, OPMT elicited the highest levels of antigen-specific IgG responses, cytokines including interleukin-2, interferon-γ, and tumor necrosis factor-α, and proliferation of lymphocytes. Importantly, the sera from mice vaccinated with OPM or OPMT neutralized more than 86% of ASF virus in vitro.
Conclusions
Our results suggest that OPMT has good immunostimulatory activities and immunogenicity in mice, and might be an appropriate candidate to elicit immune responses in swine. Our study provides valuable information on further development of a subunit vaccine against ASF.
Collapse
|
58
|
Wang T, Luo R, Sun Y, Qiu HJ. Current efforts towards safe and effective live attenuated vaccines against African swine fever: challenges and prospects. Infect Dis Poverty 2021; 10:137. [PMID: 34949228 PMCID: PMC8702042 DOI: 10.1186/s40249-021-00920-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Accepted: 11/11/2021] [Indexed: 11/10/2022] Open
Abstract
Background African swine fever (ASF) is a fatal hemorrhagic disease in domestic pigs and wild boar caused by African swine fever virus (ASFV). Since ASF has been introduced into Europe and Asia, the major pig-raising areas, posing a huge threat to the pork industry worldwide. Currently, prevention and control of ASF are basically dependent on strict biosecurity measures and stamping-out policy once ASF occurs. Main text The major risks of ASF spread are insufficient biosecurity measures and human behaviors. Therefore, a safe and effective vaccine seems to be a reasonable demand for the prevention and control of ASF. Due to the efficacy advantage over other types of vaccines, live attenuated vaccines (LAVs), especially virulence-associated genes deleted vaccines, are likely to be put into emergency and conditional use in restricted areas if ASF is out of control in a country with a huge pig population and pork consumption, like China. However, the safety, efficacy, and genetic stability of current candidate ASF LAVs require comprehensive clinical evaluations prior to country-wide field application. Several critical issues need to be addressed to commercialize an ideal ASF LAV, including a stable cell line for manufacturing vaccines, differentiation of infected from vaccinated animals (DIVA), and cross-protection from different genotypes. Conclusion A safe and effective DIVA vaccine and an accompanying diagnostic assay will facilitate the prevention, control, and eradication of ASF, which is quite challenging in the near future. Graphical Abstract ![]()
Collapse
Affiliation(s)
- Tao Wang
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150069, China
| | - Rui Luo
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150069, China.,School of Life Science Engineering, Foshan University, Foshan, 528231, China
| | - Yuan Sun
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150069, China
| | - Hua-Ji Qiu
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150069, China. .,School of Life Science Engineering, Foshan University, Foshan, 528231, China.
| |
Collapse
|
59
|
Lv C, Zhao Y, Jiang L, Zhao L, Wu C, Hui X, Hu X, Shao Z, Xia X, Sun X, Zhang Q, Jin M. Development of a Dual ELISA for the Detection of CD2v-Unexpressed Lower-Virulence Mutational ASFV. Life (Basel) 2021; 11:life11111214. [PMID: 34833090 PMCID: PMC8626036 DOI: 10.3390/life11111214] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Revised: 10/29/2021] [Accepted: 11/02/2021] [Indexed: 11/16/2022] Open
Abstract
African swine fever virus (ASFV) is an important viral pathogen infecting pigs worldwide throughout the pig industry. CD2v (an outer-membrane glycosylated protein of ASFV)-unexpressed lower-virulence mutants have appeared in China and other countries in recent years. Using OIE-recommended quantitative PCR and ELISA methods, people can accurately judge whether pigs are infected with wild-type ASFV. However, the strategy has failed to distinguish ΔCD2v lower-virulence mutants and wild-type ASFV infection. Here, we expressed and purified the CD2v and p30 proteins via CHO cells and successfully established a dual enzyme-linked immunosorbent assay (ELISA), which can be used to differentiate pigs infected with wild-type ASFV or with CD2v-unexpressed lower-virulence mutants. The dual ELISA showed excellent specificity without cross-reactions with antibodies of PRRSV, CSFV, JEV, PRV, or PPV. The dual ELISA could detect ASFV-infected positive serum samples up to dilutions of 5120 times, possessing high sensitivity. Therefore, the application of this dual ELISA approach can play an important role in ASFV epidemiology study and fill the gaps in differential diagnosis.
Collapse
Affiliation(s)
- Changjie Lv
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; (C.L.); (Y.Z.); (L.J.); (L.Z.); (C.W.); (X.H.); (X.H.); (X.X.); (X.S.)
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
| | - Ya Zhao
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; (C.L.); (Y.Z.); (L.J.); (L.Z.); (C.W.); (X.H.); (X.H.); (X.X.); (X.S.)
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
| | - Lili Jiang
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; (C.L.); (Y.Z.); (L.J.); (L.Z.); (C.W.); (X.H.); (X.H.); (X.X.); (X.S.)
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
| | - Li Zhao
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; (C.L.); (Y.Z.); (L.J.); (L.Z.); (C.W.); (X.H.); (X.H.); (X.X.); (X.S.)
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
| | - Chao Wu
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; (C.L.); (Y.Z.); (L.J.); (L.Z.); (C.W.); (X.H.); (X.H.); (X.X.); (X.S.)
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
| | - Xianfeng Hui
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; (C.L.); (Y.Z.); (L.J.); (L.Z.); (C.W.); (X.H.); (X.H.); (X.X.); (X.S.)
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
| | - Xiaotong Hu
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; (C.L.); (Y.Z.); (L.J.); (L.Z.); (C.W.); (X.H.); (X.H.); (X.X.); (X.S.)
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
| | - Ziqi Shao
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
| | - Xiaohan Xia
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; (C.L.); (Y.Z.); (L.J.); (L.Z.); (C.W.); (X.H.); (X.H.); (X.X.); (X.S.)
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
| | - Xiaomei Sun
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; (C.L.); (Y.Z.); (L.J.); (L.Z.); (C.W.); (X.H.); (X.H.); (X.X.); (X.S.)
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
| | - Qiang Zhang
- College of Biomedicine and Health, Huazhong Agricultural University, Wuhan 430070, China
- Correspondence: (Q.Z.); (M.J.)
| | - Meilin Jin
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; (C.L.); (Y.Z.); (L.J.); (L.Z.); (C.W.); (X.H.); (X.H.); (X.X.); (X.S.)
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China;
- Correspondence: (Q.Z.); (M.J.)
| |
Collapse
|
60
|
Deletion of E184L, a putative DIVA target from the pandemic strain of African swine fever virus, produces a reduction in virulence and protection against virulent challenge. J Virol 2021; 96:e0141921. [PMID: 34668772 DOI: 10.1128/jvi.01419-21] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
African swine fever (ASF) is currently causing a major pandemic affecting the swine industry and protein availability from Central Europe to East and South Asia. No commercial vaccines are available, making disease control dependent on the elimination of affected animals. Here, we show that the deletion of the ASFV E184L gene from the highly virulent ASFV-Georgia2010 (ASFV-G) isolate produces a reduction in virus virulence during the infection in swine. Forty percent (40%) of domestic pigs intramuscularly inoculated with a recombinant virus lacking the E184L gene (ASFV-G-ΔE184L) experienced a significantly (5 days) delayed presentation of clinical disease and, overall, had a 60% rate of survival when compared to animals inoculated with the virulent parental ASFV-G. Importantly, all animals surviving ASFV-G-ΔE184L infection developed a strong antibody response and were protected when challenged with ASFV-G. As expected, a pool of sera from ASFV-G-ΔE184L-inoculated animals lacked any detectable antibody response to peptides partially representing the E184L protein, while sera from animals inoculated with an efficacious vaccine candidate, ASFV-G-ΔMGF, strongly recognize the same set of peptides. These results support the potential use of the E184L deletion for the development of vaccines able to differentiate infected from vaccinated animals (DIVA). Therefore, it is shown here that the E184L gene is a novel ASFV determinant of virulence that can potentially be used to increase safety in pre-existing vaccine candidates as well as to provide them with DIVA capabilities. To our knowledge, E184L is the first ASFV gene product experimentally shown to be a functional DIVA antigenic marker. Importance: No commercial vaccines are available to prevent African swine fever. The ASF pandemic caused by the Georgia (ASFV-G) strain is seriously affecting pork production in a contiguous geographical area from Central Europe to East Asia. The only effective experimental vaccines are viruses attenuated by deleting ASFV genes associated with virus virulence. Therefore, identification of such genes is of critical importance for vaccine development. Here we report the discovery of a novel determinant of ASFV virulence, the E184L gene. Deletion of the E184L gene from the ASFV-G genome (ASFV-G-ΔE184L) produced a reduction in virus virulence and, importantly, animals surviving infection with ASFV-G-ΔE184L were protected from developing ASF after challenge with the virulent parental virus ASFV-G. Importantly, the virus protein encoded by E184L is highly immunogenic, making a virus lacking this gene a DIVA vaccine candidate that allows the differentiation of infected from vaccinated animals. Here we show that unlike what is observed in animals inoculated with the vaccine candidate ASFV-G-ΔMGF, ASFV-G-ΔE184L-inoculated animals do not mount a E184L-specific antibody response, indicating the feasibility of using the E184L deletion as the antigenic marker for the development of a DIVA vaccine in ASFV.
Collapse
|
61
|
Deletion of the A137R Gene from the Pandemic Strain of African Swine Fever Virus Attenuates the Strain and Offers Protection against the Virulent Pandemic Virus. J Virol 2021; 95:e0113921. [PMID: 34406865 DOI: 10.1128/jvi.01139-21] [Citation(s) in RCA: 65] [Impact Index Per Article: 21.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
African swine fever virus (ASFV) is causing a devastating pandemic in domestic and wild swine within an extended geographical area from Central Europe to East Asia, resulting in economic losses for the regional swine industry. There are no commercial vaccines; therefore, disease control relies on identification and culling of infected animals. We report here that the deletion of the ASFV gene A137R from the highly virulent ASFV-Georgia2010 (ASFV-G) isolate induces a significant attenuation of virus virulence in swine. A recombinant virus lacking the A137R gene, ASFV-G-ΔA137R, was developed to assess the role of this gene in ASFV virulence in domestic swine. Animals inoculated intramuscularly with 102 50% hemadsorption doses (HAD50) of ASFV-G-ΔA137R remained clinically healthy during the 28-day observational period. All animals inoculated with ASFV-G-ΔA137R had medium to high viremia titers and developed a strong virus-specific antibody response. Importantly, all ASFV-G-ΔA137R-inoculated animals were protected when challenged with the virulent parental strain ASFV-G. No evidence of replication of challenge virus was observed in the ASFV-G-ΔA137R-inoculated animals. Therefore, ASFV-G-ΔA137R is a novel potential live attenuated vaccine candidate and one of the few experimental vaccine strains reported to induce protection against the highly virulent ASFV Georgia virus that is the cause of the current Eurasian pandemic. IMPORTANCE No commercial vaccine is available to prevent African swine fever. The ASF pandemic caused by ASFV Georgia2007 strain (ASFV-G) is seriously affecting pork production in a contiguous area from Central Europe to East Asia. Here we report the rational development of a potential live attenuated vaccine strain by deleting a virus-specific gene, A137R, from the genome of ASFV-G. The resulting virus presented a completely attenuated phenotype and, importantly, animals infected with this genetically modified virus were protected from developing ASF after challenge with the virulent parental virus. ASFV-G-ΔA137R confers protection even at low doses (102 HAD50), demonstrating its potential as a vaccine candidate. Therefore, ASFV-G-ΔA137R is a novel experimental ASF vaccine protecting pigs from the epidemiologically relevant ASFV Georgia isolate.
Collapse
|
62
|
Guo Z, Zhuo Y, Li K, Niu S, Dai H. Recent advances in cell homeostasis by African swine fever virus-host interactions. Res Vet Sci 2021; 141:4-13. [PMID: 34634684 DOI: 10.1016/j.rvsc.2021.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Revised: 09/07/2021] [Accepted: 10/05/2021] [Indexed: 10/20/2022]
Abstract
African swine fever (ASF) is an acute hemorrhagic disease caused by the infection of domestic swine and wild boar by the African swine fever virus (ASFV), with a mortality rate close to 90-100%. ASFV has been spreading in the world and poses a severe economic threat to the swine industry. There is no high effective vaccine commercially available or drug for this disease. However, attenuated ASFV isolates may infect pigs by chronic infection, and the infected pigs will not be lethal, which may indicate that pigs can produce protective immunity to resistant ASFV. Immunity acquisition and virus clearances are the central pillars to maintain the host normal cell activities and animal survival dependent on virus-host interactions, which has offered insights into the biology of ASFV. This review is organized around general themes including native immunity, endoplasmic reticulum stress, cell apoptosis, ubiquitination, autophagy regarding the intricate relationship between ASFV protein-host. Elucidating the multifunctional role of ASFV proteins in virus-host interactions can provide more new insights on the initial virus sensing, clearance, and cell homeostasis, and contribute to understanding viral pathogenesis and developing novel antiviral therapeutics.
Collapse
Affiliation(s)
- Zeheng Guo
- College of Veterinary Medicine, Huazhong Agricultural University, No.1 Shizishan Street, Wuhan, Hubei 430070, China
| | - Yisha Zhuo
- College of Veterinary Medicine, Huazhong Agricultural University, No.1 Shizishan Street, Wuhan, Hubei 430070, China
| | - Keke Li
- College of Veterinary Medicine, Huazhong Agricultural University, No.1 Shizishan Street, Wuhan, Hubei 430070, China
| | - Sai Niu
- College of Veterinary Medicine, Huazhong Agricultural University, No.1 Shizishan Street, Wuhan, Hubei 430070, China
| | - Hanchuan Dai
- College of Veterinary Medicine, Huazhong Agricultural University, No.1 Shizishan Street, Wuhan, Hubei 430070, China.
| |
Collapse
|
63
|
Tran XH, Le TTP, Nguyen QH, Do TT, Nguyen VD, Gay CG, Borca MV, Gladue DP. African swine fever virus vaccine candidate ASFV-G-ΔI177L efficiently protects European and native pig breeds against circulating Vietnamese field strain. Transbound Emerg Dis 2021; 69:e497-e504. [PMID: 34582622 DOI: 10.1111/tbed.14329] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 09/04/2021] [Accepted: 09/15/2021] [Indexed: 11/29/2022]
Abstract
The recent spread of African swine fever (ASF) in the People's Republic of China and neighbouring countries in Asia has had significant economic consequences with an estimated direct cost of $55-$130 billion. This pandemic, originally detected in Republic of Georgia in 2007, has devastated the swine industry in large geographical areas of Southeast Asia with 14 countries reporting ASF outbreaks since the first documented case was confirmed in the city of Shenyang, Liaoning Province, China, on 3 August 2018. In the absence of any available vaccines, the control of ASF relies on the detection and culling of infected animals. The United States Department of Agriculture recently developed a recombinant experimental vaccine candidate, ASFV-G-ΔI177L, by deleting the I177L gene from the genome of the highly virulent pandemic ASFV strain Georgia, which efficaciouly protects pigs from the parental virus. Here, the initial studies were extended demonstrating that ASFV-G-ΔI177L is able to protect pigs against the virulent ASFV isolate currently circulating and producing disease in Vietnam with similar efficacy as reported against the Georgia strain. Comparative studies performed using a large number of pigs of European and Vietnamese origin demonstrated that a minimum protective dose of 102 HAD50 of ASFV-G-ΔI177L equally protects animals of both breeds. In concurrence with those results, the onset of immunity in these animal breed showed appearance of protection in approximately one-third of the animals by the second week post vaccination, with full protection achieved by the fourth week post vaccination. Therefore, results presented here demonstrated that ASFV-G-ΔI177L is able to induce protection against virulent Vietnameese ASFV field strains and is effective in protecting local breeds of pigs as efficiently as previously shown for European cross-bred pigs. To our knowledge, this is the first report showing the efficacy of a Georgia 2007 based vaccine candidate in Asian breed of pigs or challenged with an Asian ASFV strain.
Collapse
Affiliation(s)
- Xuan Hanh Tran
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City, Vietnam
| | - Thi Thu Phuong Le
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City, Vietnam
| | - Quang Huy Nguyen
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City, Vietnam
| | - Thanh Thuy Do
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City, Vietnam
| | - Van Dung Nguyen
- National Veterinary Joint Stock Company (NAVETCO), Ho Chi Minh City, Vietnam
| | - Cyril G Gay
- U.S. Department of Agriculture, Agricultural Research Service, Beltsville, Maryland, USA
| | - Manuel V Borca
- Agricultural Research Service, U.S. Department of Agriculture, Plum Island Animal Disease Center, Greenport, New York, USA
| | - Douglas P Gladue
- Agricultural Research Service, U.S. Department of Agriculture, Plum Island Animal Disease Center, Greenport, New York, USA
| |
Collapse
|
64
|
Report on the First African Swine Fever Case in Greece. Vet Sci 2021; 8:vetsci8080163. [PMID: 34437485 PMCID: PMC8402752 DOI: 10.3390/vetsci8080163] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Revised: 08/04/2021] [Accepted: 08/06/2021] [Indexed: 11/16/2022] Open
Abstract
African swine fever (ASF) poses a major threat to swine health and welfare worldwide. After several European countries have reported cases of ASF, Greece confirmed officially the first positive case on 5 February 2020. The owner of a backyard farm in Nikoklia, a village in Serres regional unit, Central Macedonia, reported a loss of appetite, weakness, dyspnea, and the sudden death of 6 domestic pigs. Necropsy was performed in one gilt and findings were compatible with acute to subacute septicemic disease. Predominantly, hyperemic enlargement of spleen and lymph node enlargement and/or hemorrhage were observed. Description of vague clinical signs by the farmer suggested a limited resemblance to ASF-acute infection. However, the disease could not be ruled out once septicemic condition including splenomegaly, was diagnosed macroscopically at necropsy. In addition, considering the farm’s location near to ASF protection zones, a further diagnostic investigation followed. Confirmation of the disease was obtained using a series of diagnostic tests on several tissue samples. Further clinical, molecular, and epidemiologic evaluation of the farm was performed. According to the contingency plan, authorities euthanized all 31 pigs on the farm, whilst blood testing revealed ASF virus infection. Further emergency measures were implemented to contain the spread of the disease.
Collapse
|
65
|
African Swine Fever Virus as a Difficult Opponent in the Fight for a Vaccine-Current Data. Viruses 2021; 13:v13071212. [PMID: 34201761 PMCID: PMC8310326 DOI: 10.3390/v13071212] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 06/17/2021] [Accepted: 06/19/2021] [Indexed: 12/13/2022] Open
Abstract
Prevention and control of African swine fever virus (ASFV) in Europe, Asia, and Africa seem to be extremely difficult in view of the ease with which it spreads, its high resistance to environmental conditions, and the many obstacles related to the introduction of effective specific immunoprophylaxis. Biological properties of ASFV indicate that the African swine fever (ASF) pandemic will continue to develop and that only the implementation of an effective and safe vaccine will ensure a reduction in the spread of ASFV. At present, vaccines against ASF are not available. The latest approaches to the ASFV vaccine’s design concentrate on the development of either modified live vaccines by targeted gene deletion from different isolates or subunit vaccines. The construction of an effective vaccine is hindered by the complex structure of the virus, the lack of an effective continuous cell line for the isolation and propagation of ASFV, unpredictable and stain-specific phenotypes after the genetic modification of ASFV, a risk of reversion to virulence, and our current inability to differentiate infected animals from vaccinated ones. Moreover, the design of vaccines intended for wild boars and oral administration is desirable. Despite several obstacles, the design of a safe and effective vaccine against ASFV seems to be achievable.
Collapse
|